Fig. 6From: Distinct mechanisms of resistance to fulvestrant treatment dictate level of ER independence and selective response to CDK inhibitors in metastatic breast cancerCyclin E2 levels increase after progression on fulvestrant and correlate with clinical outcome. a Representation of cyclin E2 expression in samples from three patients with ER+ breast cancer before initiation of fulvestrant treatment (pre) and upon progress during treatment (post) as determined by immunohistochemical stainings. Quantifications of cyclin E2 scoring for each pre- and post- sample are shown to the left and representative stainings are shown to the right. b Evaluation of progression-free survival (PFS) in tumors with cyclin E2 low versus high expression in ER+ breast cancer patients treated with fulvestrant in the advanced setting. Kaplan-Meier plots for PFS are shown to the left and representative stainings for low and high cyclin E2 expression are shown to the right. p value represents log-rank test for PFS between patients with high and low levels of cyclin E2 expression. Scale-bar represents 25 μm in (a, b). c Cox multivariate regression analysis of PFS according to cyclin E2 expression levels, age at diagnosis of metastasis, and site of recurrenceBack to article page